Today, new data from BI-1808 in cutaneous T-cell lymphoma were presented. The monotherapy efficacy (ORR of 40% in evaluable patients) is in line with previous numbers. The addition of pembrolizumab resulted in an ORR of 50%, which could position this as the preferred treatment.
LÄS MER
